Capricor Therapeutics
CAPR
25 hedge funds and large institutions have $6.64M invested in Capricor Therapeutics in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 12 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
54% more capital invested
Capital invested by funds: $4.32M → $6.64M (+$2.32M)
0.18% less ownership
Funds ownership: 6.6% → 6.41% (-0.18%)
24% less funds holding
Funds holding: 33 → 25 (-8)
42% less call options, than puts
Call options by funds: $995K | Put options by funds: $1.71M
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.79M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$964K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$490K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$394K |
| 5 |
Bank of New York Mellon
New York
|
+$352K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$914K |
| 2 |
VF
Virtu Financial
New York
|
-$264K |
| 3 |
Two Sigma Investments
New York
|
-$200K |
| 4 |
Goldman Sachs
New York
|
-$179K |
| 5 |
Two Sigma Advisers
New York
|
-$97K |
CAPR Hedge Fund Activity: Q3 2020 in Review
25 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2020, worth a combined $6.64M — up 54% from $4.32M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CAPR and 4 opened new positions — a net loss of 8 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was BlackRock, adding an estimated $1.79M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $914K sold.
- 25 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2020, down from 33 in Q2 2020.
- Funds reported $6.64M of Capricor Therapeutics stock for Q3 2020, up 54% quarter-over-quarter.
- 4 funds opened new Capricor Therapeutics positions in Q3 2020 and 12 closed out, a net change of -8 holders.
- The largest Capricor Therapeutics buyer in Q3 2020 was BlackRock, an estimated $1.79M added.
- The largest Capricor Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $914K sold.
Based on aggregated 13F filings for Q3 2020.